Vivos Therapeutics (VVOS) Competitors

$0.64 -0.05 (-7.10%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$0.66 +0.01 (+2.18%)

As of 05/15/2026 07:59 PM Eastern

VVOS vs. AGPU, NMTC, STRR, POCI, and NEPH

Should you buy Vivos Therapeutics stock or one of its competitors? MarketBeat compares Vivos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vivos Therapeutics include Predictive Oncology (AGPU), NeuroOne Medical Technologies (NMTC), Star Equity (STRR), Precision Optics (POCI), and Nephros (NEPH). These companies are all part of the "medical equipment" industry.

How does Vivos Therapeutics compare to Predictive Oncology?

Predictive Oncology (NASDAQ:AGPU) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Predictive Oncology had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 6 mentions for Predictive Oncology and 4 mentions for Vivos Therapeutics. Predictive Oncology's average media sentiment score of 0.69 beat Vivos Therapeutics' score of 0.47 indicating that Predictive Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vivos Therapeutics has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$120K	270.08	-$233.10M	-$12.62	N/A
Vivos Therapeutics	$17.44M	0.50	-$21.17M	-$2.07	N/A

Predictive Oncology has a beta of 3.45, indicating that its stock price is 245% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its stock price is 525% more volatile than the broader market.

Vivos Therapeutics has a net margin of -121.37% compared to Predictive Oncology's net margin of -185,476.72%. Predictive Oncology's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-185,476.72%	N/A	-970.41%
Vivos Therapeutics	-121.37%	-849.22%	-96.11%

Vivos Therapeutics has a consensus price target of $2.58, indicating a potential upside of 303.02%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivos Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Vivos Therapeutics beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Vivos Therapeutics (NASDAQ:VVOS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Vivos Therapeutics' net margin of -121.37%. NeuroOne Medical Technologies' return on equity of -98.33% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-121.37%	-849.22%	-96.11%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

Vivos Therapeutics currently has a consensus price target of $2.58, indicating a potential upside of 303.02%. NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 177.12%. Given Vivos Therapeutics' higher probable upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, NeuroOne Medical Technologies had 3 more articles in the media than Vivos Therapeutics. MarketBeat recorded 7 mentions for NeuroOne Medical Technologies and 4 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.47 beat NeuroOne Medical Technologies' score of 0.20 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies has lower revenue, but higher earnings than Vivos Therapeutics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.50	-$21.17M	-$2.07	N/A
NeuroOne Medical Technologies	$12.10M	3.00	-$3.61M	-$0.85	N/A

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NeuroOne Medical Technologies beats Vivos Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Star Equity?

Vivos Therapeutics (NASDAQ:VVOS) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Star Equity shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 33.5% of Star Equity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vivos Therapeutics currently has a consensus price target of $2.58, indicating a potential upside of 303.02%. Star Equity has a consensus price target of $28.00, indicating a potential upside of 187.77%. Given Vivos Therapeutics' higher probable upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Star Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Star Equity	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Star Equity has higher revenue and earnings than Vivos Therapeutics. Star Equity is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.50	-$21.17M	-$2.07	N/A
Star Equity	$172.16M	0.21	-$5.92M	-$2.63	N/A

In the previous week, Star Equity had 14 more articles in the media than Vivos Therapeutics. MarketBeat recorded 18 mentions for Star Equity and 4 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.47 beat Star Equity's score of -0.28 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Star Equity	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Star Equity has a net margin of -4.18% compared to Vivos Therapeutics' net margin of -121.37%. Star Equity's return on equity of -4.04% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-121.37%	-849.22%	-96.11%
Star Equity	-4.18%	-4.04%	-2.40%

Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the broader market. Comparatively, Star Equity has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Summary

Star Equity beats Vivos Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Vivos Therapeutics compare to Precision Optics?

Precision Optics (NASDAQ:POCI) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

13.7% of Precision Optics shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 14.4% of Precision Optics shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vivos Therapeutics has a consensus price target of $2.58, indicating a potential upside of 303.02%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivos Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Precision Optics has higher revenue and earnings than Vivos Therapeutics. Precision Optics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision Optics	$19.09M	1.93	-$5.78M	-$0.63	N/A
Vivos Therapeutics	$17.44M	0.50	-$21.17M	-$2.07	N/A

In the previous week, Precision Optics had 6 more articles in the media than Vivos Therapeutics. MarketBeat recorded 10 mentions for Precision Optics and 4 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.47 beat Precision Optics' score of 0.15 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision Optics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision Optics has a net margin of -17.03% compared to Vivos Therapeutics' net margin of -121.37%. Precision Optics' return on equity of -37.47% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision Optics	-17.03%	-37.47%	-19.96%
Vivos Therapeutics	-121.37%	-849.22%	-96.11%

Precision Optics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its stock price is 525% more volatile than the broader market.

Summary

Precision Optics beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Nephros?

Nephros (NASDAQ:NEPH) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Nephros has a net margin of 4.06% compared to Vivos Therapeutics' net margin of -121.37%. Nephros' return on equity of 7.66% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Vivos Therapeutics	-121.37%	-849.22%	-96.11%

41.1% of Nephros shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nephros has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	1.81	$1.19M	$0.07	44.71
Vivos Therapeutics	$17.44M	0.50	-$21.17M	-$2.07	N/A

In the previous week, Vivos Therapeutics had 2 more articles in the media than Nephros. MarketBeat recorded 4 mentions for Vivos Therapeutics and 2 mentions for Nephros. Nephros' average media sentiment score of 1.16 beat Vivos Therapeutics' score of 0.47 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nephros presently has a consensus price target of $6.00, indicating a potential upside of 91.69%. Vivos Therapeutics has a consensus price target of $2.58, indicating a potential upside of 303.02%. Given Vivos Therapeutics' higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vivos Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Nephros has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the broader market.

Summary

Nephros beats Vivos Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.79M	$3.00B	$6.38B	$12.30B
Dividend Yield	N/A	1.97%	2.81%	5.26%
P/E Ratio	-0.31	17.57	20.66	25.27
Price / Sales	0.50	269.52	552.79	74.65
Price / Cash	N/A	57.31	42.43	54.86
Price / Book	-4.01	4.33	9.87	6.90
Net Income	-$21.17M	$72.19M	$3.57B	$334.66M
7 Day Performance	-3.58%	-3.06%	0.23%	0.12%
1 Month Performance	-34.20%	-5.08%	-2.54%	-0.18%
1 Year Performance	-74.76%	36.79%	33.54%	30.62%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	3.0914 of 5 stars	$0.64 -7.1%	$2.58 +303.0%	-74.8%	$8.79M	$17.44M	N/A	160	News Coverage Upcoming Earnings
AGPU Predictive Oncology	1.1865 of 5 stars	$6.66 flat	N/A	N/A	$36.89M	$120K	N/A	30	News Coverage Earnings Report Analyst Downgrade
NMTC NeuroOne Medical Technologies	3.9632 of 5 stars	$4.39 +1.4%	$13.50 +207.5%	+5.5%	$36.46M	$12.10M	N/A	20	Earnings Report Analyst Forecast Short Interest Decrease
STRR Star Equity	3.8538 of 5 stars	$9.48 +0.2%	$16.50 +74.1%	+321.2%	$35.07M	$172.16M	N/A	1,200	Trending News Earnings Report Analyst Revision High Trading Volume
POCI Precision Optics	0.411 of 5 stars	$4.54 +1.1%	N/A	+5.5%	$34.73M	$24.42M	N/A	80	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. AGPU, NMTC, STRR, POCI, and NEPH

How does Vivos Therapeutics compare to Predictive Oncology?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Summary

How does Vivos Therapeutics compare to Star Equity?

Summary

How does Vivos Therapeutics compare to Precision Optics?

Summary

How does Vivos Therapeutics compare to Nephros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. AGPU, NMTC, STRR, POCI, and NEPH

How does Vivos Therapeutics compare to Predictive Oncology?

Do institutionals and insiders believe in AGPU or VVOS?

Does the media favor AGPU or VVOS?

Which has stronger earnings and valuation, AGPU or VVOS?

Which has more volatility & risk, AGPU or VVOS?

Is AGPU or VVOS more profitable?

Do analysts rate AGPU or VVOS?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Is VVOS or NMTC more profitable?

Do analysts rate VVOS or NMTC?

Which has more risk & volatility, VVOS or NMTC?

Does the media favor VVOS or NMTC?

Which has preferable earnings & valuation, VVOS or NMTC?

Do insiders & institutionals have more ownership in VVOS or NMTC?

Summary

How does Vivos Therapeutics compare to Star Equity?

Do insiders & institutionals have more ownership in VVOS or STRR?

Do analysts rate VVOS or STRR?

Which has preferable earnings & valuation, VVOS or STRR?

Does the media favor VVOS or STRR?

Is VVOS or STRR more profitable?

Which has more risk & volatility, VVOS or STRR?

Summary

How does Vivos Therapeutics compare to Precision Optics?

Do institutionals & insiders have more ownership in POCI or VVOS?

Do analysts prefer POCI or VVOS?

Which has higher earnings & valuation, POCI or VVOS?

Does the media prefer POCI or VVOS?

Is POCI or VVOS more profitable?

Which has more risk & volatility, POCI or VVOS?

Summary

How does Vivos Therapeutics compare to Nephros?

Is NEPH or VVOS more profitable?

Do insiders and institutionals have more ownership in NEPH or VVOS?

Which has stronger valuation and earnings, NEPH or VVOS?

Does the media prefer NEPH or VVOS?

Do analysts prefer NEPH or VVOS?

Which has more volatility and risk, NEPH or VVOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools